These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17981158)

  • 1. Structural basis of mercury- and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors.
    Lee CC; Kuo CJ; Hsu MF; Liang PH; Fang JM; Shie JJ; Wang AH
    FEBS Lett; 2007 Nov; 581(28):5454-8. PubMed ID: 17981158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase.
    Yin J; Niu C; Cherney MM; Zhang J; Huitema C; Eltis LD; Vederas JC; James MN
    J Mol Biol; 2007 Aug; 371(4):1060-74. PubMed ID: 17599357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.
    Shao YM; Yang WB; Kuo TH; Tsai KC; Lin CH; Yang AS; Liang PH; Wong CH
    Bioorg Med Chem; 2008 Apr; 16(8):4652-60. PubMed ID: 18329272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.
    Lee CC; Kuo CJ; Ko TP; Hsu MF; Tsui YC; Chang SC; Yang S; Chen SJ; Chen HC; Hsu MC; Shih SR; Liang PH; Wang AH
    J Biol Chem; 2009 Mar; 284(12):7646-55. PubMed ID: 19144641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.
    Lu IL; Mahindroo N; Liang PH; Peng YH; Kuo CJ; Tsai KC; Hsieh HP; Chao YS; Wu SY
    J Med Chem; 2006 Aug; 49(17):5154-61. PubMed ID: 16913704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease.
    Ren Z; Yan L; Zhang N; Guo Y; Yang C; Lou Z; Rao Z
    Protein Cell; 2013 Apr; 4(4):248-50. PubMed ID: 23549610
    [No Abstract]   [Full Text] [Related]  

  • 7. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
    Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
    J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
    Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
    Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features.
    Chen L; Li J; Luo C; Liu H; Xu W; Chen G; Liew OW; Zhu W; Puah CM; Shen X; Jiang H
    Bioorg Med Chem; 2006 Dec; 14(24):8295-306. PubMed ID: 17046271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits.
    Mukherjee P; Desai P; Ross L; White EL; Avery MA
    Bioorg Med Chem; 2008 Apr; 16(7):4138-49. PubMed ID: 18343121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.
    Tsai KC; Chen SY; Liang PH; Lu IL; Mahindroo N; Hsieh HP; Chao YS; Liu L; Liu D; Lien W; Lin TH; Wu SY
    J Med Chem; 2006 Jun; 49(12):3485-95. PubMed ID: 16759091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV.
    Hsu JT; Kuo CJ; Hsieh HP; Wang YC; Huang KK; Lin CP; Huang PF; Chen X; Liang PH
    FEBS Lett; 2004 Sep; 574(1-3):116-20. PubMed ID: 15358550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.
    Zhou L; Liu Y; Zhang W; Wei P; Huang C; Pei J; Yuan Y; Lai L
    J Med Chem; 2006 Jun; 49(12):3440-3. PubMed ID: 16759084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug design targeting the main protease, the Achilles' heel of coronaviruses.
    Yang H; Bartlam M; Rao Z
    Curr Pharm Des; 2006; 12(35):4573-90. PubMed ID: 17168763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.
    Lai L; Han X; Chen H; Wei P; Huang C; Liu S; Fan K; Zhou L; Liu Z; Pei J; Liu Y
    Curr Pharm Des; 2006; 12(35):4555-64. PubMed ID: 17168761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction between severe acute respiratory syndrome coronavirus 3C-like proteinase and a dimeric inhibitor by capillary electrophoresis.
    Ding L; Zhang XX; Wei P; Fan K; Lai L
    Anal Biochem; 2005 Aug; 343(1):159-65. PubMed ID: 15935325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease.
    Konno H; Wakabayashi M; Takanuma D; Saito Y; Akaji K
    Bioorg Med Chem; 2016 Mar; 24(6):1241-54. PubMed ID: 26879854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.
    Lee H; Lei H; Santarsiero BD; Gatuz JL; Cao S; Rice AJ; Patel K; Szypulinski MZ; Ojeda I; Ghosh AK; Johnson ME
    ACS Chem Biol; 2015 Jun; 10(6):1456-65. PubMed ID: 25746232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza-decaline scaffold.
    Teruya K; Hattori Y; Shimamoto Y; Kobayashi K; Sanjoh A; Nakagawa A; Yamashita E; Akaji K
    Biopolymers; 2016 Nov; 106(4):391-403. PubMed ID: 26572934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure.
    Hu T; Zhang Y; Li L; Wang K; Chen S; Chen J; Ding J; Jiang H; Shen X
    Virology; 2009 Jun; 388(2):324-34. PubMed ID: 19409595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.